Edition:
India

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

90.91USD
1:30am IST
Change (% chg)

$0.04 (+0.04%)
Prev Close
$90.87
Open
$90.64
Day's High
$91.05
Day's Low
$89.78
Volume
1,747,752
Avg. Vol
1,800,628
52-wk High
$98.97
52-wk Low
$58.61

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb Announces Extension Of The Expiration Date For Exchange Offers For Celgene Notes
Friday, 28 Jun 2019 

June 28 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB COMPANY ANNOUNCES EXTENSION OF THE EXPIRATION DATE FOR EXCHANGE OFFERS FOR CELGENE CORPORATION NOTES.BRISTOL-MYERS SQUIBB - SETTLEMENT DATE FOR EXCHANGE OFFERS IS EXPECTED TO OCCUR PROMPTLY AFTER EXPIRATION DATE AND ON OR ABOUT CLOSING DATE OF MERGER.BRISTOL-MYERS SQUIBB - EXTENDS SUCH EXPIRATION DATE TO 5:00 P.M., NEW YORK CITY TIME, ON SEPTEMBER 30.  Full Article

Celgene Corp Says U.S. FDA And EMA Accept Applications For Ozanimod For Treatment Of Relapsing Forms Of Multiple Sclerosis
Thursday, 6 Jun 2019 

June 6 (Reuters) - Celgene Corp ::CELGENE CORP - U.S. FDA AND EMA ACCEPT APPLICATIONS FOR OZANIMOD FOR TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS.CELGENE - UNDER PRESCRIPTION DRUG USER FEE ACT, FDA HAS SET ACTION DATE AS MARCH 25, 2020.CELGENE CORP - REGULATORY DECISION FROM EUROPEAN MEDICINES AGENCY IS EXPECTED IN FIRST HALF OF 2020.  Full Article

Bristol-Myers Says David Elkins Will Be Appointed Co's Executive Vice President & CFO
Wednesday, 5 Jun 2019 

June 5 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ANNOUNCES POST-CLOSING LEADERSHIP TEAM.BRISTOL-MYERS SQUIBB CO - SAMIT HIRAWAT WILL JOIN BRISTOL-MYERS SQUIBB AS CHIEF MEDICAL OFFICER, GLOBAL DRUG DEVELOPMENT.BRISTOL-MYERS SQUIBB CO - DAVID ELKINS WILL BE APPOINTED COMPANY'S EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER.BRISTOL-MYERS SQUIBB CO - RUPERT VESSEY , WILL SERVE AS PRESIDENT, RESEARCH & EARLY DEVELOPMENT.BRISTOL-MYERS SQUIBB CO - CAFORIO WILL CONTINUE TO SERVE AS CHAIRMAN OF BOARD AND CHIEF EXECUTIVE OFFICER OF COMPANY.BRISTOL-MYERS SQUIBB CO - DAVID ELKINS IS CURRENTLY CHIEF FINANCIAL OFFICER OF CELGENE.BRISTOL-MYERS - FOLLOWING DEAL CLOSE, CHARLES BANCROFT TO WORK WITH ELKINS TO ENSURE AN EFFECTIVE TRANSITION OF ALL FINANCIAL AND OPERATIONAL MATTERS.BRISTOL-MYERS SQUIBB CO - CHRIS BOERNER WILL CONTINUE IN HIS ROLE AS EXECUTIVE VICE PRESIDENT AND CHIEF COMMERCIALIZATION OFFICER.  Full Article

FDA Approves Revlimid In Combination With Rituximab For Treatment Of Follicular Lymphoma Or Marginal Zone Lymphoma
Tuesday, 28 May 2019 

May 28 (Reuters) - Celgene Corp ::FDA APPROVES REVLIMID (LENALIDOMIDE) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA OR MARGINAL ZONE LYMPHOMA.CELGENE CORP - MAA FOR REVLIMID IN COMBINATION WITH RITUXIMAB IS UNDER REVIEW BY EMA FOR TREATMENT OF RELAPSED/REFRACTORY FL AND MZL.  Full Article

Bristol-Myers Squibb Says Requisite Number Of Consents Received To Adopt Proposed Amendments With Respect To All Outstanding Notes Of Celgene Corporation
Thursday, 2 May 2019 

May 1 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB COMPANY ANNOUNCES RESULTS OF EARLY PARTICIPATION IN EXCHANGE OFFERS AND CONSENT SOLICITATIONS FOR CELGENE CORPORATION NOTES.BRISTOL-MYERS SQUIBB - REQUISITE NUMBER OF CONSENTS RECEIVED TO ADOPT PROPOSED AMENDMENTS WITH RESPECT TO ALL OUTSTANDING NOTES OF CELGENE CORPORATION.  Full Article

Celgene Q1 Earnings Per Share $2.14
Friday, 26 Apr 2019 

April 25 (Reuters) - Celgene Corp ::CELGENE REPORTS FIRST QUARTER 2019 OPERATING AND FINANCIAL RESULTS.Q1 REVENUE $4.025 BILLION VERSUS REFINITIV IBES ESTIMATE OF $4.01 BILLION.Q1 EARNINGS PER SHARE $2.14.Q1 EARNINGS PER SHARE ESTIMATE $2.43 -- REFINITIV IBES DATA.REAFFIRMING 2019 GUIDANCE AND 2020 FINANCIAL TARGETS.REVLIMID SALES FOR Q1 WERE $2,577 MILLION, AN INCREASE OF 15 PERCENT YEAR-OVER-YEAR.OTEZLA SALES FOR Q1 WERE $389 MILLION, A 10 PERCENT INCREASE YEAR-OVER-YEAR.ACQUISITION BY BRISTOL-MYERS SQUIBB EXPECTED TO CLOSE IN Q3 OF 2019.QTRLY ADJUSTED. EARNINGS PER SHARE $2.55.FY2019 EARNINGS PER SHARE VIEW $10.70, REVENUE VIEW $17.11 BILLION -- REFINITIV IBES DATA.  Full Article

Bristol-Myers Squibb Reports First Quarter Financial Results
Thursday, 25 Apr 2019 

April 25 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB REPORTS FIRST QUARTER FINANCIAL RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $1.10.Q1 GAAP EARNINGS PER SHARE $1.04.Q1 REVENUE $5.9 BILLION VERSUS REFINITIV IBES ESTIMATE OF $5.75 BILLION.Q1 EARNINGS PER SHARE ESTIMATE $1.09 -- REFINITIV IBES DATA.RAISES FY 2019 NON-GAAP EARNINGS PER SHARE VIEW TO $4.10 TO $4.20.RAISES FY 2019 GAAP EARNINGS PER SHARE VIEW TO $3.84 TO $3.94.REAFFIRMS NON-GAAP EPS GUIDANCE RANGE OF $4.10-$4.20.QTRLY U.S. REVENUES INCREASED 24% TO $3.4 BILLION IN QUARTER COMPARED TO SAME PERIOD A YEAR AGO.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $10.0 BILLION, WITH A NET CASH POSITION OF $4.0 BILLION, AS OF MARCH 31, 2019.RESULTS FOR Q1 OF 2019 INCLUDE $187 MILLION OF CELGENE-RELATED ACQUISITION AND INTEGRATION EXPENSES.COMPANY TODAY ANNOUNCED TOPLINE RESULTS FROM PHASE 2 CHECKMATE -714 TRIAL EVALUATING OPDIVO VERSUS OPDIVO PLUS YERVOY.STUDY DID NOT MEET ITS PRIMARY ENDPOINTS.QTRLY OPDIVO WORLWIDE REVENUE $1,801 MILLION VERSUS $1,511 MILLION.SEES 2019 WORLDWIDE REVENUES INCREASING IN MID-SINGLE DIGITS.QTRLY ELIQUIS WORLDWIDE REVENUE $1,925 MILLION VERSUS $1,506 MILLION.SEES 2019 GROSS MARGIN AS A PERCENTAGE OF REVENUE TO BE APPROXIMATELY 70% FOR BOTH GAAP AND NON-GAAP.QTRLY SPRYCEL WORLDWIDE REVENUE $459 MILLION VERSUS $438 MILLION.BRISTOL-MYERS SQUIBB - SALE OF UPSA CONSUMER HEALTH BUSINESS TO TAISHO PHARMACEUTICAL FOR $1.6 BILLION IS ANTICIPATED TO BE COMPLETED IN JULY 2019.  Full Article

Celgene Corp And Acceleron Pharma Announce Submission Of Luspatercept Biologics License Application To U.S. FDA
Friday, 5 Apr 2019 

April 5 (Reuters) - Celgene Corp ::CELGENE CORPORATION AND ACCELERON PHARMA ANNOUNCE SUBMISSION OF LUSPATERCEPT BIOLOGICS LICENSE APPLICATION TO U.S. FDA.CELGENE CORP - EMA MARKETING APPLICATION FOR BOTH INDICATIONS PLANNED FOR Q2:19.CELGENE CORP - BLA SUBMISSION INCLUDES BOTH MYELODYSPLASTIC SYNDROMES AND BETA-THALASSEMIA INDICATIONS.CELGENE CORP - COMPANIES ALSO PLAN TO SUBMIT A MARKETING APPLICATION TO EUROPEAN MEDICINES AGENCY IN Q2 OF 2019..  Full Article

Bristol-Myers Squibb And Celgene Received Request For Additional Information And Documentary Materials From FTC
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB - CO, CELGENE RECEIVED REQUEST FOR ADDITIONAL INFORMATION AND DOCUMENTARY MATERIALS FROM FTC.BRISTOL-MYERS SQUIBB - PARTIES UNDERSTAND THAT FTC’S REVIEW IS FOCUSED ON MARKETED AND PIPELINE PRODUCTS FOR THE TREATMENT OF PSORIASIS..BRISTOL-MYERS SQUIBB - REQUEST FOR ADDITIONAL INFORMATION FROM FTC IN CONNECTION WITH THE FTC’S REVIEW OF THE MERGER.BRISTOL-MYERS SQUIBB - BOTH PARTIES CONTINUE TO EXPECT THAT THE MERGER WILL BE CONSUMMATED IN THE THIRD QUARTER OF 2019.BRISTOL-MYERS SQUIBB CO - PARTIES WILL CONTINUE TO WORK COOPERATIVELY WITH THE FTC.  Full Article

Bristol-Myers Squibb Co - Urges Shareholders To Vote "For" Proposed Celgene Transaction On White Proxy Card
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB FILES INVESTOR PRESENTATION HIGHLIGHTING SIGNIFICANT BENEFITS OF PENDING TRANSACTION WITH CELGENE.BRISTOL-MYERS SQUIBB CO - URGES SHAREHOLDERS TO VOTE "FOR" PROPOSED CELGENE TRANSACTION ON WHITE PROXY CARD.  Full Article

RPT-BUZZ-U.S. stocks weekly: Not half bad

(Repeats from Friday. Updates chart) ** S&P 500 snaps 3-week winning streak, slips 0.3% as all eyes are on G20 Summit. Though index finishes first half up 17.3%, the best start to a year since 1997 ** That said, charts suggest risk the SPX may have a bumpy ride ahead ** And while the DJI may still see another push , the Nasdaq's high hurdles may be too high ** This as lagging small caps may loom large ** Most sectors decline: Real estate and utilities fall most, while fin